REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jun 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-06-01

Reporting Person: STAHL NEIL (EVP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-01	Common Stock	M	4527	$268.4	Acquired	28477	Direct
2017-06-01	Common Stock	F	2612	$464.98	Disposed	25865	Direct
2017-06-01	Common Stock	F	1068	$464.98	Disposed	24797	Direct
2017-06-01	Common Stock	M	6017	$145.7	Acquired	30814	Direct
2017-06-01	Common Stock	F	1885	$464.98	Disposed	28929	Direct
2017-06-01	Common Stock	F	2167	$464.98	Disposed	26762	Direct
2017-06-02	Common Stock	S	100	$466.33	Disposed	26662	Direct
2017-06-02	Common Stock	S	100	$469.83	Disposed	26562	Direct
2017-06-02	Common Stock	S	100	$470.49	Disposed	26462	Direct
2017-06-02	Common Stock	S	100	$472.1	Disposed	26362	Direct
2017-06-02	Common Stock	S	100	$474.82	Disposed	26262	Direct
2017-06-02	Common Stock	S	100	$475.33	Disposed	26162	Direct
2017-06-02	Common Stock	S	100	$476.52	Disposed	26062	Direct
2017-06-02	Common Stock	S	100	$479.0	Disposed	25962	Direct
2017-06-02	Common Stock	S	309	$480.71	Disposed	25653	Direct
2017-06-02	Common Stock	S	695	$481.64	Disposed	24958	Direct
2017-06-02	Common Stock	S	808	$482.56	Disposed	24150	Direct
2017-06-02	Common Stock	S	200	$483.42	Disposed	23950	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-01	Non-Qualified Stock Option (right to buy)	$145.7	M	6017	Disposed	2017-12-17	Common Stock (6017)	Direct
2017-06-01	Non-Qualified Stock Option (right to buy)	$268.4	M	4527	Disposed	2017-12-17	Common Stock (4527)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect
Common Stock	5000	Indirect
Common Stock	5647	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 309 shares of Company stock on June 2, 2017 at prices ranging from $480.30 to $480.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.

F3: Represents volume-weighted average price of sales of 695 shares of Company stock on June 2, 2017 at prices ranging from $481.25 to $481.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.

F4: Represents volume-weighted average price of sales of 808 shares of Company stock on June 2, 2017 at prices ranging from $482.00 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.

F5: Represents volume-weighted average price of sales of 200 shares of Company stock on June 2, 2017 at prices ranging from $483.11 to $483.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.